Avila appoints Andrew Hirsch CFO
This article was originally published in Scrip
Executive Summary
Avila Therapeutics, a biotechnology company developing targeted covalent drugs, has made Andrew Hirsch its first chief financial officer. Mr Hirsch joins Avila from Biogen Idec where he served for 10 years, most recently as vice-president of corporate strategy and M&A.